MedEx answers any queries you might have regarding Xtandi-40 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Xtandi 40 mg (Enzalutamide) is a modern anti-tumor drug representing the androgen antagonist, intended for the treatment of prostate cancer in men treated with Docetaxel or other drug used for chemotherapy.
Xtandi 40 mg has proved effective during clinical trials. Studies have shown that the drug is well-tolerated and (when used regularly) able to reduce the tumor.
Enzalutamide is an androgen receptor antagonist. It affects different parts of signal way. The active substance prevents the connection of testosterone with androgen receptors and their link to DNA and translocation into the core. It results in the death of prostate cancer cells and the reduction of tumor.
Indications for use of Xtandi 40 mg
Xtandi 40 mg is used for the treatment of metastatic prostate cancer in adult men (if the disease was asymptomatic, the patient hasn’t taken chemotherapy or has been treated with the other drugs, but the androgen replacement therapy didn’t give results).
Enzalutamide can cause:
headache and weakness;
seizures, joint and muscle pain;
insomnia, anxiety, vertigo;
burning or numbness under the skin;
fatigue and sleepiness;
skin reddening, hand or leg swelling;
cold symptoms (runny nose, sore throat and sneezing);
sense of fever.
Xtandi 40 mg is used for the treatment of prostate cancer in men. It is not prescribed for women, as they aren’t exposed to this disease. If for some reasons the women use this medication, they shouldn’t plan the pregnancy. The drug components can negatively affect the fetus and cause miscarriage.
Xtandi 40 mg is contraindicated to the children under the age of 18 and patients with individual intolerance to the drug components, when the patient has acute allergic reaction.
Way of use and dosage
Xtandi 40 mg is taken orally once a day in the amount of 4 capsules (160 ml) with or without meal. The duration of treatment is individual; it depends on the development of the disease. If you notice the side effects that don’t cause damage to the health, the drug dosage should be reduced to 80-120 mg a day. After the disappearance of unpleasant symptoms, the dose should be increased again.
Combination with other drugs
Be careful while mixing Xtandi 40 mg with the other drugs, inhibitors and inductors. During the treatment with Xtandi, you should avoid carbamazepine, rifabutin, rifampicin, phenytoin and phenobarbital.
The use of St. John’s wort can reduce the efficiency of Enzalutamide. If the use of strong inductors is unavoidable, the dose of Xtandi 40 mg should be increased. The medication reduces the effect of midazolam, omeprazol, warfarin, cyclosporine, quinidine, sirolimus, ergotamine and other drugs.